Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. A. Nauck

Do GLP-1-Based Therapies Increase Cancer Risk?

Diabetes Care

English

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The Benefits by Far Outweigh the Potential Risks

English

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

English

Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA)

English

Pharmacokinetic, Insulinotropic, and Glucagonostatic Properties of GLP-1 [7?36 Amide] After Subcutaneous Injection in Healthy Volunteers. Dose-Response-Relationships

English

Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 Amide]) in Patients With NIDDM

English

Pharmacokinetic, Insulinotropic, and Glucagonostatic Properties of GLP-1 [7?36 Amide] After Subcutaneous Injection in Healthy Volunteers. Dose-Response-Relationships

English

Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. A. Nauck

Do GLP-1-Based Therapies Increase Cancer Risk?

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The Benefits by Far Outweigh the Potential Risks

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA)

Pharmacokinetic, Insulinotropic, and Glucagonostatic Properties of GLP-1 [7?36 Amide] After Subcutaneous Injection in Healthy Volunteers. Dose-Response-Relationships

Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 Amide]) in Patients With NIDDM

Pharmacokinetic, Insulinotropic, and Glucagonostatic Properties of GLP-1 [7?36 Amide] After Subcutaneous Injection in Healthy Volunteers. Dose-Response-Relationships

Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients